Thermo Fisher Scientific Reports First Quarter 2024 Results
First Quarter 2024 Highlights
-
First quarter revenue was
$10.34 billion . -
First quarter GAAP diluted earnings per share (EPS) increased 4% to
$3.46 . -
First quarter adjusted EPS increased 2% to
$5.11 . -
Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. This included several analytical instruments: the Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography system, offering higher resolution, faster results, and streamlined workflows for identifying contaminants in water; the Thermo Scientific™ LInspector™ Edge In-line Mass Profilometer to enhance battery safety, performance and production; and the Thermo Scientific™ TruScan™ G3 Handheld Raman Analyzer, a next-generation handheld device for the rapid identification of chemical compounds used in drug production. We also launched the new Axiom™ PangenomiX Array, a high-throughput array for use in human genomic studies across global populations, including disease risk and detection research as well as population-scale disease research programs.
-
Continued to strengthen our industry-leading commercial engine and deepen our trusted partner status with customers to accelerate innovation and enhance productivity with the ultimate goal of improving patient care. Examples during the quarter included the launch of the CorEvitas syndicated clinical registry in generalized pustular psoriasis to address an unmet need for real-world evidence related to outcomes for patients with this rare disease, and the expansion of our portfolio of services at our GMP lab in
Middleton, Wisconsin to include qPCR-based biosafety testing capabilities to enable significantly faster results versus traditional testing methods. We also continued to collaborate with customers to improve health outcomes, developing next-generation sequencing-based companion diagnostics to help identify patients for precision cancer therapies.
-
Active quarter of capital deployment, repurchasing
$3.0 billion of stock and increasing our dividend by 11 percent.
“We are very pleased to deliver another quarter of strong financial results,” said
Casper added, “Our team continues to enable the success of our customers while demonstrating incredibly strong commercial execution and operational discipline. This positions us to deliver differentiated performance in 2024, as we continue to create value for all of our stakeholders and build an even brighter future for our company.”
First Quarter 2024
Revenue for the quarter declined 3% to
GAAP Earnings Results
GAAP diluted EPS in the first quarter of 2024 increased 4% to
Non-GAAP Earnings Results
Adjusted EPS in the first quarter of 2024 increased 2% to
Annual Guidance for 2024
Use of Non-GAAP Financial Measures
Adjusted EPS, adjusted net income, adjusted operating income, adjusted operating margin, free cash flow, organic revenue growth and Core organic revenue growth are non-GAAP measures that exclude certain items detailed after the tables that accompany this press release, under the heading “Supplemental Information Regarding Non-GAAP Financial Measures.” The reconciliations of GAAP to non-GAAP financial measures are provided in the tables that accompany this press release.
Note on Presentation
Certain amounts and percentages reported within this press release are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.
Conference Call
About
Safe Harbor Statement
The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, including our pending acquisition of
Additional Information and Where to Find It
This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any common shares or American Depositary Shares of
THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, AN ADS LETTER OF TRANSMITTAL, ACCEPTANCE FORM FOR SHARES AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9, AS THEY MAY BE AMENDED FROM TIME TO TIME, CONTAIN IMPORTANT INFORMATION. INVESTORS AND SHAREHOLDERS OF OLINK ARE URGED TO READ THESE DOCUMENTS CAREFULLY BECAUSE THEY, AND NOT THIS DOCUMENT, GOVERN THE TERMS AND CONDITIONS OF THE TENDER OFFER, AND BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SUCH PERSONS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR COMMON SHARES AND AMERICAN DEPOSITARY SHARES.
The tender offer materials, including the offer to purchase, the related ADS letter of transmittal and acceptance form for shares and certain other tender offer documents, and the solicitation/recommendation statement and other documents filed with the
Condensed Consolidated Statements of Income (unaudited) |
|
|
|
|
|
|
|
|
||||||
|
|
Three months ended |
||||||||||||
|
|
|
|
% of |
|
|
|
% of |
||||||
(Dollars in millions except per share amounts) |
|
2024 |
|
Revenues |
|
2023 |
|
Revenues |
||||||
Revenues |
|
$ |
10,345 |
|
|
|
|
$ |
10,710 |
|
|
|
||
Costs and operating expenses: |
|
|
|
|
|
|
|
|
||||||
Cost of revenues (a) |
|
|
6,040 |
|
|
58.4 |
% |
|
|
6,437 |
|
|
60.1 |
% |
Selling, general and administrative expenses (b) |
|
|
1,731 |
|
|
16.7 |
% |
|
|
1,646 |
|
|
15.4 |
% |
Amortization of acquisition-related intangible assets |
|
|
551 |
|
|
5.3 |
% |
|
|
606 |
|
|
5.7 |
% |
Research and development expenses |
|
|
331 |
|
|
3.2 |
% |
|
|
346 |
|
|
3.2 |
% |
Restructuring and other costs (c) |
|
|
29 |
|
|
0.3 |
% |
|
|
112 |
|
|
1.0 |
% |
Total costs and operating expenses |
|
|
8,682 |
|
|
83.9 |
% |
|
|
9,147 |
|
|
85.4 |
% |
Operating income |
|
|
1,663 |
|
|
16.1 |
% |
|
|
1,563 |
|
|
14.6 |
% |
Interest income |
|
|
279 |
|
|
|
|
|
146 |
|
|
|
||
Interest expense |
|
|
(363 |
) |
|
|
|
|
(300 |
) |
|
|
||
Other income/(expense) (d) |
|
|
10 |
|
|
|
|
|
(46 |
) |
|
|
||
Income before income taxes |
|
|
1,589 |
|
|
|
|
|
1,363 |
|
|
|
||
Provision for income taxes (e) |
|
|
(281 |
) |
|
|
|
|
(46 |
) |
|
|
||
Equity in earnings/(losses) of unconsolidated entities |
|
|
23 |
|
|
|
|
|
(25 |
) |
|
|
||
Net income |
|
|
1,331 |
|
|
|
|
|
1,292 |
|
|
|
||
Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest |
|
|
4 |
|
|
|
|
|
3 |
|
|
|
||
Net income attributable to |
|
$ |
1,328 |
|
|
12.8 |
% |
|
$ |
1,289 |
|
|
12.0 |
% |
|
|
|
|
|
|
|
|
|
||||||
Earnings per share attributable to |
|
|
|
|
|
|
|
|
||||||
Basic |
|
$ |
3.47 |
|
|
|
|
$ |
3.34 |
|
|
|
||
Diluted |
|
$ |
3.46 |
|
|
|
|
$ |
3.32 |
|
|
|
||
Weighted average shares: |
|
|
|
|
|
|
|
|
||||||
Basic |
|
|
382 |
|
|
|
|
|
386 |
|
|
|
||
Diluted |
|
|
384 |
|
|
|
|
|
388 |
|
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of adjusted operating income and adjusted operating margin |
|
|
|
|
|
|
|
|
||||||
GAAP operating income |
|
$ |
1,663 |
|
|
16.1 |
% |
|
$ |
1,563 |
|
|
14.6 |
% |
Cost of revenues adjustments (a) |
|
|
15 |
|
|
0.1 |
% |
|
|
41 |
|
|
0.4 |
% |
Selling, general and administrative expenses adjustments (b) |
|
|
19 |
|
|
0.2 |
% |
|
|
8 |
|
|
0.1 |
% |
Restructuring and other costs (c) |
|
|
29 |
|
|
0.3 |
% |
|
|
112 |
|
|
1.0 |
% |
Amortization of acquisition-related intangible assets |
|
|
551 |
|
|
5.3 |
% |
|
|
606 |
|
|
5.7 |
% |
Adjusted operating income (non-GAAP measure) |
|
$ |
2,278 |
|
|
22.0 |
% |
|
$ |
2,330 |
|
|
21.8 |
% |
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of adjusted net income |
|
|
|
|
|
|
|
|
||||||
GAAP net income attributable to |
|
$ |
1,328 |
|
|
|
|
$ |
1,289 |
|
|
|
||
Cost of revenues adjustments (a) |
|
|
15 |
|
|
|
|
|
41 |
|
|
|
||
Selling, general and administrative expenses adjustments (b) |
|
|
19 |
|
|
|
|
|
8 |
|
|
|
||
Restructuring and other costs (c) |
|
|
29 |
|
|
|
|
|
112 |
|
|
|
||
Amortization of acquisition-related intangible assets |
|
|
551 |
|
|
|
|
|
606 |
|
|
|
||
Other income/expense adjustments (d) |
|
|
(11 |
) |
|
|
|
|
46 |
|
|
|
||
Provision for income taxes adjustments (e) |
|
|
|
|
|
|
|
|
(171 |
) |
|
|
||
Equity in earnings/losses of unconsolidated entities |
|
|
(23 |
) |
|
|
|
|
25 |
|
|
|
||
Adjusted net income (non-GAAP measure) |
|
$ |
1,959 |
|
|
|
|
$ |
1,956 |
|
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of adjusted earnings per share |
|
|
|
|
|
|
|
|
||||||
GAAP diluted EPS attributable to |
|
$ |
3.46 |
|
|
|
|
$ |
3.32 |
|
|
|
||
Cost of revenues adjustments (a) |
|
|
0.04 |
|
|
|
|
|
0.10 |
|
|
|
||
Selling, general and administrative expenses adjustments (b) |
|
|
0.05 |
|
|
|
|
|
0.02 |
|
|
|
||
Restructuring and other costs (c) |
|
|
0.08 |
|
|
|
|
|
0.29 |
|
|
|
||
Amortization of acquisition-related intangible assets |
|
|
1.44 |
|
|
|
|
|
1.56 |
|
|
|
||
Other income/expense adjustments (d) |
|
|
(0.03 |
) |
|
|
|
|
0.12 |
|
|
|
||
Provision for income taxes adjustments (e) |
|
|
0.13 |
|
|
|
|
|
(0.44 |
) |
|
|
||
Equity in earnings/losses of unconsolidated entities |
|
|
(0.06 |
) |
|
|
|
|
0.06 |
|
|
|
||
Adjusted EPS (non-GAAP measure) |
|
$ |
5.11 |
|
|
|
|
$ |
5.03 |
|
|
|
||
|
|
|
|
|
|
|
|
|
||||||
Reconciliation of free cash flow |
|
|
|
|
|
|
|
|
||||||
GAAP net cash provided by operating activities |
|
$ |
1,251 |
|
|
|
|
$ |
729 |
|
|
|
||
Purchases of property, plant and equipment |
|
|
(347 |
) |
|
|
|
|
(458 |
) |
|
|
||
Proceeds from sale of property, plant and equipment |
|
|
4 |
|
|
|
|
|
6 |
|
|
|
||
Free cash flow (non-GAAP measure) |
|
$ |
908 |
|
|
|
|
$ |
277 |
|
|
|
Business Segment Information |
|
Three months ended |
||||||||||||
|
|
|
|
% of |
|
|
|
% of |
||||||
(Dollars in millions) |
|
2024 |
|
Revenues |
|
2023 |
|
Revenues |
||||||
|
|
|
|
|
|
|
|
|
||||||
Revenues |
|
|
|
|
|
|
|
|
||||||
Life Sciences Solutions |
|
$ |
2,285 |
|
|
22.1 |
% |
|
$ |
2,612 |
|
|
24.4 |
% |
Analytical Instruments |
|
|
1,687 |
|
|
16.3 |
% |
|
|
1,723 |
|
|
16.1 |
% |
|
|
|
1,109 |
|
|
10.7 |
% |
|
|
1,108 |
|
|
10.3 |
% |
Laboratory Products and Biopharma Services |
|
|
5,723 |
|
|
55.3 |
% |
|
|
5,763 |
|
|
53.8 |
% |
Eliminations |
|
|
(460 |
) |
|
-4.4 |
% |
|
|
(496 |
) |
|
-4.6 |
% |
Consolidated revenues |
|
$ |
10,345 |
|
|
100.0 |
% |
|
$ |
10,710 |
|
|
100.0 |
% |
|
|
|
|
|
|
|
|
|
||||||
Segment income and segment income margin |
|
|
|
|
|
|
|
|
||||||
Life Sciences Solutions |
|
$ |
840 |
|
|
36.8 |
% |
|
$ |
836 |
|
|
32.0 |
% |
Analytical Instruments |
|
|
400 |
|
|
23.7 |
% |
|
|
421 |
|
|
24.4 |
% |
|
|
|
294 |
|
|
26.5 |
% |
|
|
280 |
|
|
25.3 |
% |
Laboratory Products and Biopharma Services |
|
|
744 |
|
|
13.0 |
% |
|
|
793 |
|
|
13.8 |
% |
Subtotal reportable segments |
|
|
2,278 |
|
|
22.0 |
% |
|
|
2,330 |
|
|
21.8 |
% |
Cost of revenues adjustments (a) |
|
|
(15 |
) |
|
-0.1 |
% |
|
|
(41 |
) |
|
-0.4 |
% |
Selling, general and administrative expenses adjustments (b) |
|
|
(19 |
) |
|
-0.2 |
% |
|
|
(8 |
) |
|
-0.1 |
% |
Restructuring and other costs (c) |
|
|
(29 |
) |
|
-0.3 |
% |
|
|
(112 |
) |
|
-1.0 |
% |
Amortization of acquisition-related intangible assets |
|
|
(551 |
) |
|
-5.3 |
% |
|
|
(606 |
) |
|
-5.7 |
% |
Consolidated GAAP operating income |
|
$ |
1,663 |
|
|
16.1 |
% |
|
$ |
1,563 |
|
|
14.6 |
% |
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
||||||
(a) Adjusted results in 2024 and 2023 exclude charges for inventory write-downs associated with large-scale abandonment of product lines. Adjusted results in 2023 exclude |
||||||||||||||
(b) Adjusted results in 2024 and 2023 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, and charges/credits for changes in estimates of contingent acquisition consideration. |
||||||||||||||
(c) Adjusted results in 2024 and 2023 exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, abandoned facility, and other expenses of headcount reductions and real estate consolidations. Adjusted results in 2023 also exclude |
||||||||||||||
(d) Adjusted results in 2024 and 2023 exclude net gains/losses on investments. |
||||||||||||||
(e) Adjusted results in 2024 and 2023 exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes, and the tax impacts from audit settlements. |
||||||||||||||
Note: |
||||||||||||||
Consolidated depreciation expense is |
Organic and Core organic revenue growth |
|
Three months ended |
|
|
|
|
|
Revenue growth |
|
-3% |
|
Acquisitions |
|
0% |
|
Currency translation |
|
0% |
|
Organic revenue growth (non-GAAP measure) |
|
-4% |
|
COVID-19 testing revenue |
|
-1% |
|
Core organic revenue growth (non-GAAP measure) |
|
-3% |
|
|
|
|
|
Note: |
|
||
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release. |
|
Condensed Consolidated Balance Sheets (unaudited) |
|
|
|
|
||
|
|
|
|
|
||
|
|
|
|
|
||
(In millions) |
|
2024 |
|
2023 |
||
|
|
|
|
|
||
Assets |
|
|
|
|
||
Current assets: |
|
|
|
|
||
Cash and cash equivalents |
|
$ |
5,499 |
|
$ |
8,077 |
Short-term investments |
|
|
1,751 |
|
|
3 |
Accounts receivable, net |
|
|
7,931 |
|
|
8,221 |
Inventories |
|
|
5,133 |
|
|
5,088 |
Other current assets |
|
|
3,326 |
|
|
3,200 |
Total current assets |
|
|
23,640 |
|
|
24,589 |
Property, plant and equipment, net |
|
|
9,324 |
|
|
9,448 |
Acquisition-related intangible assets, net |
|
|
16,048 |
|
|
16,670 |
Other assets |
|
|
4,241 |
|
|
3,999 |
|
|
|
43,843 |
|
|
44,020 |
Total assets |
|
$ |
97,095 |
|
$ |
98,726 |
|
|
|
|
|
||
Liabilities, redeemable noncontrolling interest and equity |
|
|
|
|
||
Current liabilities: |
|
|
|
|
||
Short-term obligations and current maturities of long-term obligations |
|
$ |
4,451 |
|
$ |
3,609 |
Other current liabilities |
|
|
9,486 |
|
|
10,403 |
Total current liabilities |
|
|
13,937 |
|
|
14,012 |
Other long-term liabilities |
|
|
6,378 |
|
|
6,564 |
Long-term obligations |
|
|
31,157 |
|
|
31,308 |
Redeemable noncontrolling interest |
|
|
119 |
|
|
118 |
Total equity |
|
|
45,504 |
|
|
46,724 |
Total liabilities, redeemable noncontrolling interest and equity |
|
$ |
97,095 |
|
$ |
98,726 |
Condensed Consolidated Statements of Cash Flows (unaudited) |
|
|
|
|
||||
|
|
|
|
|
||||
|
|
Three months ended |
||||||
|
|
|
|
|
||||
(In millions) |
|
2024 |
|
2023 |
||||
|
|
|
|
|
||||
Operating activities |
|
|
|
|
||||
Net income |
|
$ |
1,331 |
|
|
$ |
1,292 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
|
||||
Depreciation and amortization |
|
|
837 |
|
|
|
859 |
|
Change in deferred income taxes |
|
|
(253 |
) |
|
|
(146 |
) |
Other non-cash expenses, net |
|
|
123 |
|
|
|
257 |
|
Changes in assets and liabilities, excluding the effects of acquisitions |
|
|
(787 |
) |
|
|
(1,533 |
) |
Net cash provided by operating activities |
|
|
1,251 |
|
|
|
729 |
|
|
|
|
|
|
||||
Investing activities |
|
|
|
|
||||
Purchases of property, plant and equipment |
|
|
(347 |
) |
|
|
(458 |
) |
Proceeds from sale of property, plant and equipment |
|
|
4 |
|
|
|
6 |
|
Proceeds from cross-currency interest rate swap interest settlements |
|
|
64 |
|
|
|
2 |
|
Acquisitions, net of cash acquired |
|
|
— |
|
|
|
(2,704 |
) |
Purchases of investments |
|
|
(1,758 |
) |
|
|
(2 |
) |
Other investing activities, net |
|
|
7 |
|
|
|
14 |
|
Net cash used in investing activities |
|
|
(2,030 |
) |
|
|
(3,142 |
) |
|
|
|
|
|
||||
Financing activities |
|
|
|
|
||||
Net proceeds from issuance of debt |
|
|
1,205 |
|
|
|
— |
|
Net proceeds from issuance of commercial paper |
|
|
— |
|
|
|
1,027 |
|
Repayment of commercial paper |
|
|
— |
|
|
|
(523 |
) |
Purchases of company common stock |
|
|
(3,000 |
) |
|
|
(3,000 |
) |
Dividends paid |
|
|
(135 |
) |
|
|
(117 |
) |
Other financing activities, net |
|
|
110 |
|
|
|
20 |
|
Net cash used in financing activities |
|
|
(1,821 |
) |
|
|
(2,593 |
) |
|
|
|
|
|
||||
Exchange rate effect on cash |
|
|
22 |
|
|
|
(31 |
) |
Decrease in cash, cash equivalents and restricted cash |
|
|
(2,578 |
) |
|
|
(5,037 |
) |
Cash, cash equivalents and restricted cash at beginning of period |
|
|
8,097 |
|
|
|
8,537 |
|
Cash, cash equivalents and restricted cash at end of period |
|
$ |
5,519 |
|
|
$ |
3,500 |
|
|
|
|
|
|
||||
Free cash flow (non-GAAP measure) |
|
$ |
908 |
|
|
$ |
277 |
|
|
|
|
|
|
||||
|
|
|
|
|
||||
|
|
|
|
|
||||
Note: |
||||||||
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release. |
||||||||
|
Supplemental Information Regarding Non-GAAP Financial Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of acquisitions/divestitures and the effects of currency translation. We also report Core organic revenue growth, which is reported revenue growth, excluding the impacts of COVID-19 testing revenue, and excluding the impacts of acquisitions/divestitures and the effects of currency translation. We report these measures because
We report adjusted operating income, adjusted operating margin, adjusted net income, and adjusted EPS. We believe that the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:
- Certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction/acquisition-related costs, including changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating costs.
- Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating facilities. We exclude these costs because we believe that the costs related to restructuring activities are not indicative of our normal operating costs.
- Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, including gains/losses on investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and the early retirement of debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.
- The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer companies.
- The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast accurately for future periods.
We report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.
The non-GAAP financial measures of
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423741228/en/
Media Contact Information:
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Investor Contact Information:
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
Source: